Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2023 and business progress for the third quarter of 2023. Revenue for the […]
Autor: Firma Bavarian Nordic
Bavarian Nordic to Host Third Quarter 2023 Results Conference Call and Webcast
Bavarian Nordic A/S (OMX: BAVA) will announce its 2023 third quarter results on Thursday, November 16, 2023. The management of Bavarian Nordic will host a conference call at 2:00 pm […]
Bavarian Nordic Awarded Another Contract to Supply Smallpox Vaccines for EU Strategic Reserve
Bavarian Nordic A/S (OMX: BAVA) announced today, that it has been awarded another contract valued at more than EUR 11 million to supply its MVA-BN® smallpox vaccine to rescEU, a strategic […]
Bavarian Nordic Receives USD 120 Million Contract for the Manufacturing of Smallpox and Mpox Vaccine from the U.S. Government
Contract award will support manufacturing of new bulk vaccine to partly replenish the inventory used for the mpox outbreak in 2022 Aims to strengthen the long-term U.S. stockpiling of […]
Bavarian Nordic Publishes Annual Report 2022
Bavarian Nordic A/S (OMX: BAVA) today published its Annual Report for 2022. The consolidated, audited results were in line with the preliminary results, announced on January 16, 2023. The full […]
Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate
First subject vaccinated in Phase 3 clinical trial evaluating potential of the VLP-based candidate, ABNCoV2 as a booster COVID-19 vaccine Trial will assess non-inferiority of ABNCoV2 compared to Comirnaty® in […]
Bavarian Nordic Enters Multiple Vaccine Contracts with Governments in Response to Global Monkeypox Outbreak
A number of contracts of varying size have been signed Deliveries to start immediately aiming to ensure a rapid response to the current monkeypox outbreak Company upgrades its financial […]